178 related articles for article (PubMed ID: 2079378)
21. [Research and development of new oral cephems, cefixime and cefdinir].
Sakane K; Kawabata K; Inamoto Y; Yamanaka H; Takaya T
Yakugaku Zasshi; 1993 Sep; 113(9):605-26. PubMed ID: 8229662
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457
[TBL] [Abstract][Full Text] [Related]
23. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
Stewart AG; Bauer MJ; Butkiewicz D; Hinton A; Henderson A; Harris PNA; Paterson DL
Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
[TBL] [Abstract][Full Text] [Related]
24. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
Wise R; Andrews JM; Ashby JP; Thornber D
Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.
Yu KW; Chin NX; Neu HC
Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):652-9. PubMed ID: 1396779
[TBL] [Abstract][Full Text] [Related]
27. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
Babini GS; Yuan M; Livermore DM
Antimicrob Agents Chemother; 1998 May; 42(5):1168-75. PubMed ID: 9593145
[TBL] [Abstract][Full Text] [Related]
28. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
Bedenić B; Singer S
Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
[TBL] [Abstract][Full Text] [Related]
29. Comparative microbiological activity and pharmacokinetics of cefprozil.
Wise R
Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):839-45. PubMed ID: 7889957
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
[TBL] [Abstract][Full Text] [Related]
31. Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.
Biedenbach DJ; Jones RN
J Clin Microbiol; 1994 Feb; 32(2):559-62. PubMed ID: 8150976
[TBL] [Abstract][Full Text] [Related]
32. Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.
Biedenbach DJ; Jones RN; Erwin ME
J Clin Microbiol; 1993 Oct; 31(10):2828-30. PubMed ID: 8253998
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
Neu HC; Saha G; Chin NX
Antimicrob Agents Chemother; 1989 Oct; 33(10):1795-800. PubMed ID: 2589845
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Dec; 38(12):2902-4. PubMed ID: 7695280
[TBL] [Abstract][Full Text] [Related]
35. The threat of resistance to the new oral cephalosporins.
Cullmann W
Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
[TBL] [Abstract][Full Text] [Related]
36. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
Westblom TU; Gudipati S; Midkiff BR
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):691-3. PubMed ID: 2226500
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
Kayser FH
Infection; 1994; 22(5):370-5. PubMed ID: 7843823
[TBL] [Abstract][Full Text] [Related]
38. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Cappelletty DM; Rybak MJ
Antimicrob Agents Chemother; 1996 May; 40(5):1148-52. PubMed ID: 8723456
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity and beta-lactamase stability of LY163892.
Pelosi E; Fontana R
Eur J Clin Microbiol Infect Dis; 1988 Aug; 7(4):549-51. PubMed ID: 3141170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
